Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : GILD) Presents Phase 3 Clinical Data in HIV-1 at IDWeek 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:18am CEST

Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone. In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data are being presented at IDWeek 2017 in San Diego (Session 228).

These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs, said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-nave patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.

In Study 1878, a total of 577 virologically suppressed adults with HIV taking regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their bPI regimen or to switch to open-label coformulated BIC/FTC/TAF once daily. At the primary endpoint of Week 48, switching to BIC/FTC/TAF was non-inferior to continuing on a bPI regimen with 1.7 percent of patients in each group having HIV-1 RNA =50 c/mL (difference: 0.0 percent, 95 percent CI: -2.5 percent to 2.5 percent, p=1.00); the proportion of patients with HIV-1 RNA

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10/20 GILEAD SCIENCES : FDA approves new cancer treatment with Israeli pedigree
10/20 GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating High..
10/20 GILEAD SCIENCES : Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
10/19 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/19 GILEAD SCIENCES : Study Findings from Gilead Sciences Provide New Insights into ..
10/19 GILEAD SCIENCES : Patent Issued for Salts of HIV Inhibitor Compounds (USPTO 9783..
10/19 GILEAD SCIENCES : Patent Issued for Processes and Intermediates for Preparing an..
10/19 GILEAD SCIENCES : names new head of oncology therapeutics
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
More news
News from SeekingAlpha
10/20 CytoDyn Dresses HIV Patients In CCR5 Halloween 'Mask'
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 3 THINGS, OCTOBER 20, 2017 : Gilead's Big Day, Celgene's Bad News In Crohn's, Br..
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
Financials ($)
Sales 2017 25 966 M
EBIT 2017 15 929 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 85,3 $
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912
EXELIXIS, INC.84.17%8 091